Q4 2019 Earnings Call
[music].
Good day and welcome to the Morone Bio innovations fourth quarter 2019 earnings Conference call. Today's conference is being recorded at this time I'd like to turn the conference over to Miss Linda more General counsel.
Good afternoon, everyone and thanks for joining our call.
Welcome to the 2019 fourth quarter earnings conference call on their own bio innovations.
On the call today, our CEO Pam Morone.
President and CFO, Jim Boys, and Chief Commercial Officer, Kevin Campbell.
If you please refer to slide two I would like to remind you that this conference call may contain statements regarding managements expectations hopes beliefs intentions or strategies regarding the future I suppose projections forecasts or other characterizations of future up them or circumstance.
Yes.
Statements are based on managements current expectations and beliefs concerning future developments and the potential effects on the company.
There can be no assurance that future developments affecting the company will be those that management has anticipated.
Such statements involve a number of risks and uncertainties some of which are beyond management's control or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these statements.
Important factors that could cause differences are contained in the reports filed by the company with the Securities Exchange Commission, including under the heading risk factors and elsewhere in the company's annual report on form 10-K for the year ended 2018 and in our earnings release posted on the company's website.
Should one or more of these risks or uncertainties materialize, Oh should any of managements assumptions prove incorrect actual results may vary in material respects from those discussed today.
And he guidance that management may offer in this conference call represents a point in time estimate.
The company expressly disclaims any obligation to revise or update any guidance or other forward looking statements to reflect events or circumstances that may arise. After the date of this call.
After our remarks, we will hold a question answer session I.
Ill now turn the call over to our President and CFO, Jim Boyd Jim.
Thank you Linda.
Thank you to everyone for joining us on the call.
If you would turn to slide three.
Fiscal year 2019 was a high watermark for Morone bio.
Record revenues of $29.4 million, an increase of 38%.
Were driven by double digit sales growth in the venerate and regalia product families and partial you yourself from the pro farm and jet AG acquisitions.
In the United States, we saw strong growth in both our specialty crop business and our seed treatment businesses.
Talk crops for 2019 were soybean corn nuts, especially almonds and pistachios varies led by strawberries grapes and our cultivated garden segment.
From 2015 to 2019, our compounded annual growth rate for revenue was 31.6%.
First the single digits for the AG industry in general and approximately 15% for biologicals over the same period.
Looking forward, we expect to see continued strong growth from our legacy portfolio and also strong growth from our international markets as Pro farm adds geographic diversification with significant additions to our business in Europe and Latin America.
The pro farm portfolio also gives us multinational access to the new and growing large market segments of bio nutrients and bio stimulants.
Which complements our base bio protection portfolio.
Together.
We expect even stronger revenue growth in 2020 than we experienced in 2019.
In 2019, our seed treatment business grew to be approximately a third of our total net revenues.
The combination of pro farm and our domestic seed treatment businesses should give our second and third quarters, our strongest revenue.
In the United States early forecast for row crops in 2020 indicate a rebound in corn and soybean acres.
With acres that went on plant as last year coming back into production this year.
However, we continue to see AG retailers and distributors operating under a just in time inventory approach as they balance the more positive industry crop forecast with inventory positions from the prior season.
As I look at 2019 full year numbers I'm, most pleased with the 56% growth and gross profit dollars from 2018 to 2019, which is indicative of our path to adjusted EBITDA breakeven.
Strong sales and a favorable mix of higher margin products brought the gross margin to a record 54.9%.
630 basis point improvement.
We have now seems five quarters, a gross margin above 50% on top of six quarters of double digit revenue growth.
Full year operating expenses of $44.1 million included $7.9 million in specific transaction litigation and acquisition related expenses as well as Profarma operating expenses.
Excluding those items for a true apples to apples comparison.
Operating expenses were $6.4 million higher than last year or approximately $1.6 million per quarter, which reflects the plan 2019 strategic investments in our commercial organization and key R&D projects and in line with our previous Guy.
Yes.
As we look back on our 2019 resolve the benefits of those investments have paid off with a 38% increase in revenues and a positive field trial resolve results for the key R&D projects, specifically, our breakout new bio oversight and our next generation instructive.
Side and Mattersight.
Net loss for the year reflected our previously mentioned $7.9 million in specific transaction litigation and acquisition related expenses as well as the addition of pro farm.
And $7.6 million and noncash charges related to the estimated fair value of warrants under our new financing facility for an apples to apples to apples year over year comparison of $21.7 million versus $21.8 million or approximately flat.
In addition, cash used in operations for the full year was up $2 million to $21.4 million compared to $19.4 million in 2018.
Cash usage in 2019 includes the previously mentioned $7.9 million in acquisition and litigation related expenses as well as profile.
Without those expenses cash usage would've been approximately $13.5 million or $1.1 million per month.
Our core business performed as expected as our adjusted EBITDA loss in 2019 was $16 million approximately flat with the $15.7 million last year again, reflecting our increased investments in the commercial team and R&D.
Turning to slide four.
We closed out the fourth quarter was 17% revenue growth and our fifth consecutive quarter of gross margins of 50% or greater.
As you know 2019 was a challenging year in agriculture, because of weather and trade headwinds.
Continued adoption of our Biopesticide portfolio against this backdrop speech to devalue growers are experiencing with our strong portfolio of products.
We had our first full quarter of sales of pro foreign spiral nutrients seed treatment in Europe.
We are extremely pleased with the early contributions from pull farm and with the inroads they are making into the international see treatments and Polaris market.
The integration of Profarma into our business is going very well with many positive opportunities for leverage and synergies arising in both companies.
Gross margins improved 530 basis points to a record 55.8% largely due to sales mix.
Operating expenses in the fourth quarter were $11.9 million as compared to $8.3 million in the fourth quarter of 2018.
One way back out the $800000 in specific transactions legal settlement and acquisition related expenses and that first full quarter Pro farms operations. Our operating expenses were in line with our historic average even in light of our quarterly investment in our commercial team and keep pipeline projects.
The net loss in the fourth quarter of 2019 was $10.1 million as compared with a net loss of $5.6 million in the fourth quarter of 2018.
The loss includes the $800000 and specific transaction related legal settlement and acquisition related expenses as well as 1.3 million dollar noncash charges associated with our new warrant facility.
Our adjusted EBITDA loss increased by $1.3 million.
Cash used in operations was up $2.4 million inline with our previous guidance, which included our increased investment in key R&D projects and the expansion of our commercial team as well as profile.
The message here is clear.
We continue to closely monitor and manage our operating expenses to bring in our longer term strategic objectives.
2019 was a pivotal year in their own Bios history.
We delivered exceptional growth in our core portfolio entered two new market segments for bio nutrients and Biostimulants made steady improvements in our overall margins.
Strategically managed our operating expenses and significantly advanced our breakout novel Bio oversight and next generation insecticide and the Mattersight products.
From here, we see a path to achieving profitability and a positive adjusted EBITDA level of operations.
It will take accelerating revenue growth.
Global market expansion strong margin improvements and tight expense the CRO control, but we believe are achievable because we have the experience capable employees and a strong science underlying F and effective product portfolio that generates an attractive ROI for our grower customers.
And with that I would like to turn the call over Japan for her comments.
Thank you Jim.
I would underscore Jim's comments that 2019 was a transformational here from our own bio as we show on slide five.
In addition to our robust financial performance in 2019.
We launched our bio unite program to expand the base business successfully completed two compelling acquisition.
Demonstrated positive field trials and toxicology test result in support of our answer dissipated breakout products gained key regulatory approvals to support future growth and completed a carbon footprint study ever products lessening, our strong commitment to sustainable agriculture.
If you would turn to slide six we launched about even like program in the marketplace and growing 2019, but in fact it is just formalizing in approach we've taken from the start integrated pest management is central to meeting the global needs for sustainable food production.
Logical products are ideal tools and holistic integrated pest management program as they give growers news sustainable options within their existing production practices.
Through bio your night or harnessing the power of biology, with the performance of chemistry to him from healed and drive greater returns for the grower.
All while improving sustainability.
A portion of the additional investment we made an R&D in 2019 wants to provide data to prove the value of buying you like on the farm for example in 2019.
We experienced a more than 400% increase venerate bio insecticide and on and without bothering me like strategy.
It's a successful on farm tool that drove growth in 2019, and as a strategy will continue to expand and 2020 and beyond.
Another example of by every night in corn includes test results from our new product pace setter, a new formulation of regalia tank mixed with the standard chemical fungicide.
The tank mixture drove a yield increase of approximately seven bushels per acre over either product used alone.
Likewise in trials pro farms product Tech mixed with the standard chemical fungicide, probably yield increase of at least six bushels per acre over either product used alone.
In addition in a completely biological program profile this product in combination with our pace setter Saad eight partial yield boost per acre over the standard fungicide and at least for bushels over pro far or pacesetter used alone.
Finally, we also saw comparable test results in soybeans for these combinations in corn, that's where our ROI for pace setter would be five to one and in soybeans eight to one.
As we've discussed today the early contributions of our recent acquisitions stoppage at AG assets and pro form have that impressive.
Oh smashed perfectly with our bio you like approach.
It took me for to slide seven.
So far in particular gives us a new platform in the fast growing $4.6 billion seed treatment market.
In fact over a third of our business in 2019 was derived from row crops. Given the <unk> recent acquisition of pro form we have positioned to significantly expand this business and become a leading player in the global row crop and seek treatment marketplace.
We believe the partial sales we saw in 2019, where a positive indicator of the immediate value of the acquisition.
Longer term, we think the real synergies will then how customers integrate these new offerings for plant nutrition and plant health along with our biopesticide into their crop production programs as we demonstrated and 2900 field trials.
Integration will be the key to successful expansion of the jet and product lines as well and will be directing additional field trials to support this effort.
The jet AD product line also provides the potential for geographic expansion.
As we show on slide eight.
On the cost of broadening our geographic reach in no small part because of our recent acquisitions a.
Approximately 90% of our business has historically been from the U.S. market.
By 2021, however, we expect that nets mix just shift significantly due to both Profarma and continued progress on registrations of our products and new countries.
As you might anticipate.
Given the potential for Profarma Europe will become our second largest geographical presence in the shorter term burned by Brazil, and the rest of Latin America over a longer period.
Well smaller and scope on the international front I don't want to overlook that we also entered into two new distribution partnerships with two Canadian crop input suppliers and 29 team and we just announced signing a new distributor for insecticide and she like.
Our international expansion needs to be supported with field trial data generated in the countries where the products are used.
This is important both for growers in for regulatory approval and are part of the strategic investment Jim mentioned earlier on slide nine you can see this shift with a particular emphasis on the large agricultural markets in Latin America.
I would note that these data are from Rome buyers legacy portfolio alone as we did not own pro farm until late 2019.
We added the pro form field trials for 2020, the international component of the mix will increase significantly.
As previously mentioned, we strategically increased our operating expenses slightly.
Slide 10 illustrate some 2019 results no R&D programs regulatory expansions and research partnerships.
As an example test using commercial rates for our novel Bio herbicide demonstrated control other target we need a dreaded Palmer amaranth approaching that have a current post emergent chemical herbicide.
These positive results move our novel Bio herbicide products to its next phase of development, which includes toxicology crop tolerance test for additional weed control and data showing effective commercial applications in growers integrated pest management system.
In late 2019, we also announced positive results from U.S. field trials of our next generation, Nevada side insecticide.
He's still trials confirmed higher yields and cost effective control of yield robbing insects and image nodes in corn that work equivalent to or better than current industry chemicals standards.
Several key regulatory approvals came to fruition and 2019 as well.
The Galliers label in Brazil was expanded and our new novel Biofungicide market in the U.S. targets was approved in the in additional markets of Mexico, Canada in California.
In addition haven received approval in Canada, well Grandevo and venerate were approved in Mexico for the control of the Asian, Citrus psyllid that spreads the devastating citrus screening disease.
Oh extend our reach into numerous fruit and vegetable crops.
We've also taken steps to address the evolving rapidly growing cannabis and hot markets.
Our gallium backs Biofungicide was approved for use on cannabis in Canada, while our venerates IGI label was approved for use on cannabis and the California market.
Further.
The nationwide opportunity arising from the passage of the 2018 farm belt, which legalize the cultivation of happened the United States paved the way for regalia Starkest Biofungicide registrations for you. So I'm not an exciting new crop, which will have its official opening season in 2020.
In December 2019, regardless targets for two of the first of only 10 pesticide products that EPA approved for use on half of the initial have seen the.
This marks the first time that EPA has allowed crop protection products for health and represents a significant milestone and growth opportunity for the company.
Our expansion and growth strategy also focuses on our ability to be a partner of choice in emerging technologies.
We announced two such research collaborations in 2019.
The first with Compass minerals plant in this nutrition is designed to develop specialty plant nutrient products enhanced with our micro organisms.
Second without lagrow Leverages, a subset of our 18000, plus microorganism collection was there bio stimulant products to enhance crop yield and quality.
Both have the potential to cost effectively expand our presence in the bio nutrition and the bio stimulant markets.
I am pleased as discussed with you today, our recently commissioned study to determine the greenhouse gas effect effects of selected Morone bio pesticides and plant health products compared with conventional chemical pesticides products.
We believe this to be a first of a kind study on the greenhouse graft gas impact of Biopesticide.
Based on a comparative assessment of manufacturing processes.
Labeled rates and seasonal use practices using their own bio products, what on average potentially resulting in net reductions of greenhouse gas emissions of 69% to 91%.
Our 39 to 46 kilograms of C O two equivalents per acre per year.
This is significant and something we believe will reflect well in a new U.S.G. study we are conducting.
Needless to say 2019 was a busy year, if you turn to slide 11.
I wanted to close out the call and showcase the progress we've made as a company not only from an operational perspective, but from a financial standpoint from 2015 to 2019, we have delivered a revenue compound annual growth rate of 31.6% and a steadily and consistently increased our growth gross profit dollars, which demo.
Restricts the potential of scale in our business.
As many of you know in December I for newly announced that I'll be retiring some of the position of CEO of Merrill by renovations. However, I plan to stay involved with the company as a board member in consultant.
Well, our CEO search is still underway. This likely will serve as my final earnings call at their own bio. So I wanted to take a moment to thank all of you who believed in and contributed to our incredible success of the company.
Your unwavering support throughout the years has allowed morone bio innovation to become the industry leader in biological that it is today.
To our employees.
Investors customers partners and other stakeholders.
Sincere. Thank you we could not have done it without your support with that I'd like to turn the call over to the operator to be our begin our culinary session operator.
Absolutely she'd like to ask a question. Please a signal by pressing star one on your telephone keypad. If you are using his speakerphone. Please make sure you mute function is turned off to like your signal to richer equipment again press star one to ask a question well first start with Sameer Joshi from H.C. Wainwright. Please go ahead Sir.
Thanks, Good afternoon and Jim.
Hi.
HM.
Flurry of future and congratulations on the problems.
Cheap.
Thank you will not.
The first question relates to EMEA is beautiful and poor and go to one side Oh do still on track to generated revenues and going you got to be one or the bank they changed.
What we we know what we did while we were doing some of the additional steps studies that E. T. I called for Oh, one for we actually developed a better version or one five and we're contemplating that we might want to resubmit. The two of them together and then that will accelerate the approval.
015, so rather than have one.
First and then another one delayed we'd actually have a better ones sooner. So I I don't think Kevin can I don't I don't see how it will be able to be on the market 21, no. So it'll it'll it'll be pushed that'll be better in the longer term because that's the newer version will be faster to market, but not push that for yeah, but not push that far on.
Right.
HM.
Just wondering whether the revenues go up for this year.
Have you Oh spelled out or how much was organic growth was scrum just bag in school phone.
No we haven't we don't break out our segments, but.
No.
We really feel we acquired Profarma at the perfect timing and it's really ready to take off and we're really pleased with the positive impact we've seen so far.
There are lot of a synergistic opportunities.
And growth opportunities up for the two companies together.
So we're really excited about their future.
Right right, Kevin do you want to add anything about yeah.
Kevin do you want to say anything about the revenue projections yeah. Yeah. No. This is Kevin and thanks, Jim we're pretty talking that we should build on their 2019 success by adding to that double digit growth that we saw venerate and medallion core crops.
A few other things first of all well launching stargates fungicide in California is our largest market for this product also we're having a full year of sales with a recently acquired jet AG.
We're building on that bio you'd night concept than almonds, and as Pam talked about we're expanding our pacesetter into new crops like soybeans and corn.
There's another outside we see and then a this year is that this the recovery of the soybean acres will help us solidify our domestic see treatments business and the addition of pro forma will help us expand internationally. So overall, we're looking forward to robust 2020.
Understood.
And ER as we go on slide eight where you talk about to the forecasted the.
Yeah, the new distribution or <unk>.
Can you give us some color on which brought us. So you should expect to see in Yodle, But Africa has again South America.
Listen that's Australia.
Seven would you like to talk about that yeah, So right now and.
If you look at the map right now is Europe is mainly the pro forma <unk> Europe Middle East Africa, I'm serious countries, mainly the pro form products and then Latin America. It is mainly pro form with some.
Some NBR and of course, North America is primarily.
And more realm bio products, but as we go forward, where we're seeing the opportunity implement for example of all the regions around the world.
Immediately and North America, followed while Latin America fault, then by Europe that Mo bio products in what the pro form products. We see there's lot of synergies we see there's lot of complementary nature. So for example, and North America looking at both the seed treatment opportunity in the fall.
Other opportunity of putting pro form with the N.B. I products Latin America, we're doing joint testing on in 100.
You will scale demos demonstration site with and see treatment and some foyer opportunities with M.B., I and and profile products. The in Europe, the pro form products to them as dominant for next couple of years as we get a registrations of a call products in that region.
Understood Thanks for that kinda.
So stepping back up the grainy 19, or 28 gain was a great 35, 38% growth.
Okay.
And in that issue you have these new acquisitions or do you expect similar levels of group for the next couple of years or.
I would there be at least mood brought some additional acquisitions, but maybe in the pipeline.
[noise] a this is Jim.
I would expect our revenue growth to actually accelerate in 2020, and 2021 and just keep growing thereafter for that matter.
And as far as M&A activity.
I think you know.
A lot of people are coming to us we see companies every week, a new company every week.
Looking to partner with Us and I and I think we would consider companies, but only companies who had a you know strong revenue growth.
That would be accretive on an E, but ER basis.
ER and and.
Sorry, we got a phone going off here, a lot, but it'd be accretive on a revenue or earnings basis.
And.
And beach attractive multiples I'm, sorry, we got distracted by somebody I phone [laughter] going on.
Right right right.
And Oh, I think I may have asked this question.
But it's good to have more like either to win bio rather the company or would you would see expanding distribution.
Keeping movies.
I think it booked it it's keeping then and with like what that we we like.
Companies had a proprietary technology like synergistic with ours and as he said that are can give us some revenue growth.
A quick be accretive.
And Ah be attractive multiples.
Okay. Kevin this is Kevin so.
Pam just talked about the M&A side of things, but from my perspective, we're looking at adding additional distribution globally, but more specifically, we're looking at adding distribution in the mid west of U.S. for pay set of products and the the bio unite strategy with the on the pro form.
And.
Our pay set of products in Latin America, we see rapid expansion there was no pro form and then B I product. So we'll be adding distribution there both the seed and the boiler side of the business.
And then Asia, we're just started penetrating that a little of that so we look forward to additional partners in that region of the world.
Understood.
Oh, the rest of my questions offline. Thanks for taking my question.
Thank you.
Thank you for a question once again, if she'd like to ask a question. Please signaled by pressing star one on your telephone keypad NDC Sunday question has been on church <unk> start to two moves yourself from the Q. We'll next go with that Ian Gilson. Some Zacks investment. Please go ahead.
Good afternoon, ladies yeah, I am good high school was little corridor.
Huh.
Last year long [laughter] split there anything or where you actually had an increase.
The third quarter fourth quarterly revenue.
I was saying 29 to Uh huh.
Slows a bit those who dropped.
Plus the fight from food equipments that we've made.
[laughter] treatments were a significant increase.
Within the product mix and their overall revenue. So so what were the drivers zones or revenue.
To your in being pretty 90 versus 22 in the fourth cool.
Oh, Hi, Jim Boyd.
Yep.
I think I think we didn't have any drags in in the fourth quarter over fourth quarter. We just had some some products that were flat.
We had a very positive increase in our specialty crop business and everything else performed well, but the mix you know just the performance of the mix was it was such that it because the margins to approve it maybe you can comment on the the horrible Midwest whether that affected the seed treatment business.
Yeah, So, let's see I was referring to right.
So a couple of things there overall do as mentioned earlier on especially business saw really good growth, especially with a regalia and our majestene I'm zeljko in Nevada side, but as you might recall last summer due to the wet weather we had probably.
10% to 15% reduction in the soybean acres in the Midwest.
Vis a vis and if you look at our seed treatment. This is one of our key crops is actually soybeans. So what were doing is we are working through some of the inventory over the last few months.
From that decrease in soybean acres, but the parts of the no is I was just looking at some perspective plantings U.S. The a does not come into the end of March but looking at some early forecast. It appears the soybean acres or go to rebound significantly this year and too.
29 team.
2021, 2020 significantly above 2019, and they might not be back to 2018 levels, but we see good rebound so were seeing a positive momentum going into this season as the soybean acres in the corn acres rebound from the Midwest with our seed treatment business.
Okay as we are.
So going forward Oh.
I noticed we've had a very little based tax expense.
<unk> there was that due to a principal.
Yes.
Since the acquisition yes.
Oh, Okay as we go through this year.
You mentioned that you feel that the a middle of the a the sentences corridor.
We're going to show significant game.
The year over year, that's correct.
Well.
What we said was that the second and third quarter.
Would be our strongest quarters.
We actually have fat expect somewhat of a smoothing effect or because of.
Well, if you'll remember right a couple of quarters ago, we talked about at first and fourth quarter being our strongest because the the advent of the seed treatment business, but with pro farm or being added to that business. They their business actually starts a little earlier in the year than ours and so it makes sense.
Talking now shifted into the second and third quarter, but we would expect strong growth in every quarter.
Yeah.
Your question really was is as we look at this season will turn into revenue in the year.
Are we going to show Ah Onez basically Mo.
So a lot your increase in the second is the quota versus the first in terms of dollar.
In terms of dollar size, yes, so you're up your second and third quarters, where it would be bigger than your first and fourth in terms of size he's talking about growth well true of girls to also growth okay sorry.
Okay. Okay, that's certainly our.
You said you show, the who was at 400% increase in Poland treatment.
Yep.
<unk> is what does that does the.
The second quarter.
Well I mean, you old where does that fall then the we're pretty well over the flowering seasonally for Olin.
Yeah, so that Kevin answer that so that that's a growth was due to our largely due to our bio night for naval arm to arm them, but I believe and Kevin can talk about the timing.
Yeah. So.
The the blue the Bloom seasons really more regarding our with Gallia fungicide product and then for from there on then.
Route the spring and summer bonds is when you see naval Orange worms come out and that's where we there's two or three different times of applications throughout the year. That's when we use our bio United strategy of putting data right in with the sand chemistry. So it's not kind of one month in one quarter, it's spread out between.
The seasons of spring to summer, depending on the insect pressure.
Okay.
The third they're almost didn't know every other significant product for you when you compare it to cooling soybeans.
Oh, Yeah Almond is one of our top three crops that we have right now.
<unk> <unk>.
Looking at the end market.
All right. So there's no load of discussion as to whether the market is.
The legal market.
Is as big as many tax authorities or thoughts, particularly within the state of California.
So I know down to them they sell them part of the study that was the you.
A lot called the year at smaller shops at Bay City gum boss.
Uh huh.
Is that still.
The near term product for you or all be looking at all so beyond 21.
2022.
Yeah and.
We combined HAMP cannabis and agreed how this business all under our our portfolio called cultivated garden and we've seen some nice successes with ER with this portfolio last year little bit harder to track because sometimes you can send a product to a customer.
They can either put into a fruit and vegetables or into Canada as or have but overall the portfolio is growing interesting enough I was reading an article yesterday or a couple of days ago and that and indicated that have come to the third largest.
You asked crop by revenue in the future [laughter], but our experience in California per se is that it's going through a lot of turmoil and transition expressively booked a harvesting storage and processing challenges that they need to overcome so we are best again, the area, but where.
We're we're not betting the future and they are not where it's opportunistic opportunity for us as we go for it.
This is good so he is not dedicated to several tools to that market.
Ah, Yes, do we have and individual who manages they overall direction in insight for that business yes.
So good density or not.
This concludes today's question and answer session I'd like to keep the floor back over to the moderators for closing or additional remarks.
Thank you again for joining us today and for your interest in Rome, Bio funny 19, with a landmark here for our company.
I believe we are uniquely positioned to meet growing demands for new solutions and the integrated pest management and plant health program, our revenue growth underscores the value of our bodies night approach, which harnesses the power of biology, but the performance of chemistry.
Our recent strategic acquisition and R&D investments have the potential to greatly expand or opportunity and into the bio stimulant bio nutrition markets.
Hi, I'm proud of the accomplishments of them Rabatin I firmly believe that Morone bio is poised for significant shareholder value creation creation over the longer term. Thank you.
This concludes today's call. Thank you all for your participation you may not go ahead and disconnect.
[music].